Stock LSTA LISATA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Lisata Therapeutics, Inc.

Equities

LSTA

US1280583022

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-07 pm EDT 		5-day change 1st Jan Change
2.75 USD -0.72% Intraday chart for Lisata Therapeutics, Inc. +0.73% +0.73%
Apr. 23 Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer MT
Apr. 23 Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Adjusts Lisata Therapeutics' Price Target to $15 From $6, Keeps Buy Rating
MT
HC Wainwright Adjusts Price Target on Caladrius Biosciences to $6 From $8, Reiterates Buy Rating
MT
CALADRIUS BIOSCIENCES : Chardan Suspends Coverage on Caladrius Biosciences at Buy Rating With $6 Price Target
MT
CALADRIUS BIOSCIENCES : Brookline Capital Management Adjusts Caladrius Biosciences PT to $10 From $7, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LSTA Stock
  4. News Lisata Therapeutics, Inc.
  5. Analyst Reco.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW